Clinical Trials Logo

Lung Neoplasms clinical trials

View clinical trials related to Lung Neoplasms.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06405815 Completed - Clinical trials for Lung Cancer, Nonsmall Cell

A Radiomic Model for Risk of Local Recurrence and DFS for T3 and T4 Non-small Cell Lung Cancer

Start date: January 1, 2021
Phase:
Study type: Observational

The investigators retrospectively collected the participants with T3 and T4, N0-2, M0 NSCLC patients resected between January 2013 to December 2021 for training and internal validation. The Clinical data, preoperative laboratory results and images were collected. High-risk margins were defined as R1 or R2 surgical margins or local recurrence during follow-up, and the investigators also collected the disease-free survival time. On the Deepwise multi-modal research platform, the images were semi-automatically segmented and expanded outward by 3mm to obtain the peritumor tissue. PyRadiomics was used to extract the radiomic features. LASSO was used to select the features and tumor radiomics model, peritumor model and combined model were built using 5-fold cross-validation. And it was further tested on the independent cohort. Discrimination was assessed by using the C-index and area under the receiver operating characteristic curve (AUC), sensibility, specificity.

NCT ID: NCT06347965 Completed - Sarcopenia Clinical Trials

Construction and Effect Evaluation of the Low Load Blood Flow Restriction Training Program for Lung Cancer Patients Complicated With Sarcopenia During Chemotherapy

Start date: February 1, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to verify the effectiveness and safety of the low load blood flow restriction training program. The intervention effect, tolerance and compliance of low load blood flow restriction training and progressive resistance training on lung cancer patients complicated with sarcopenia during chemotherapy will be compared, in order to provide new ideas for improving or reversing sarcopenia. The main questions it aims to answer are: Can low load blood flow restriction training improve sarcopenia in chemotherapy induced lung cancer patients? Which training method is more effective and tolerable between low load blood flow restriction training and progressive resistance training? Participants will be randomly divided into 3 groups: 1. Routine care group (Control group, CON): The researchers will provide participants with regular exercise and dietary guidance. 2. Low load blood flow restriction group (LL-BFRT): The researchers will provide participants with a low load blood flow restriction training program constructed by our research group. 3. Progressive resistance training group (PRE): The researchers will provide participants with progressive resistance training.

NCT ID: NCT06331975 Completed - Clinical trials for Non Small Cell Lung Cancer

Radiomics and Radiogenomics of Non-small Cell Lung Cancer

Start date: June 12, 2018
Phase: N/A
Study type: Interventional

In this study, the radiomic characteristics and a broad range of genetic aberrations in lung adenocarcinomas will be evaluated. Investigators will assess changes in the radiomic and genetic profiles during targeted therapies in a subset of patients harboring treatable mutations. Patients undergoing targeted therapies will also be evaluated for variations in genomic profile and radiomic signature during follow-up

NCT ID: NCT06292052 Completed - Lung Cancer Clinical Trials

Relation Between Tumor-draining Lymph Nodes Metastasis Pattern and Non-small Cell Lung Cancer Neoadjuvant Immunotherapy Effectiveness

Start date: January 1, 2017
Phase:
Study type: Observational

The goal of this retrospective cohort analysis is to discover the impact of the involvement extent of tumor-draining lymph nodes (TDLNs) in patients who received neoadjuvant immunochemotherapy. The main question it aims to answer is the role of TDLN in the prediction of treatment effectiveness. Researches will compare tumor-draining lymph nodes metastasis (mTDLNs) group and non-draining lymph nodes metastasis (mNDLNs) group to see whether different metastatic patterns of mediastinal lymph nodes can indicate the treatment effectiveness.

NCT ID: NCT06289023 Completed - Brain Metastases Clinical Trials

HA-WBRT-SIB for Brain Metastasis of Lung Cancer

Start date: January 1, 2016
Phase: Phase 2
Study type: Interventional

Patients with lung cancer and brain metastases undergo HA-WBRT-SIB using image-guided radiotherapy, receiving a total dose of 30-36 Gy delivered in 18-20 fractions to the whole brain (CTV), while the dose to the GTV is boosted to 44 Gy-52 Gy in 18-20 fractions, five times a week. The optimal mean dose (Dmean) to the bilateral hippocampus should optimally be ≤ 8 Gy, with a mandatory maximum dose (Dmax) to the hippocampus not exceeding 10 Gy; the preferred Dmean to the hippocampus PRV should optimally be ≤ 9 Gy, while the mandatory Dmax to the hippocampus PRV should be ≤ 12 Gy. The HVLT-R immediate recall scores are obtained at baseline and 1, 3, and 6 months after treatment.

NCT ID: NCT06232967 Completed - Clinical trials for Non-small-cell Lung Cancer (NSCLC)

PPIO-006 Primary Tumor Resection for IVa NSCLC

Start date: April 1, 2023
Phase:
Study type: Observational

The goal of this mutli-center observational study is toinvestigate the impact of primary tumor resection (PTR) on the long-term survival of patients with non-small-cell lung cancer (NSCLC) and dry pleural dissemination (DPD). The main question it aims to answer is: whether primary tumor resection improve long-term survival of NSCLC patients with dry pleural dissemination.

NCT ID: NCT06224504 Completed - Clinical trials for Non-Small Cell Lung Cancer

Clinical Effectiveness of Combining Mindfulness-Based Stress Reduction With Exercise Interventione

Start date: January 1, 2021
Phase: N/A
Study type: Interventional

This study is to assess the clinical effectiveness of combining Mindfulness-Based Stress Reduction (MBSR) with exercise intervention in improving anxiety, depression, sleep quality, and mood regulation in Chinese patients with non-small cell lung cancer (NSCLC).The control group received conventional psychological nursing care, while the intervention group received a combination of MBSR and exercise therapy. Pre- and post-treatment scores of anxiety, depression, sleep quality, and the BSRS-5 were compared.

NCT ID: NCT06195657 Completed - Lung Neoplasms Clinical Trials

Pre-operative Localization of Ground Glass Solitary Pulmonary Nodules

SLIDINGWIRE
Start date: March 2012
Phase:
Study type: Observational

Objectives: The main drawback of the hook-wire technique for locating ground glass nodules before video assisted thoracoscopic surgery (VATS) resection is the risk of the hook dislodging during single lung ventilation as the lung collapses. In order to reduce the friction of the thread in the wall, the investigators modified the technique by first positioning a catheter in the chest wall and introducing the carrying needle through the catheter. The objective was to evaluate the success rate and complications of this technique. Material and Methods : the investigators retrospectively included all patients undergoing VATS resection of solitary lung nodules after localization using the sliding wire technique.

NCT ID: NCT06168916 Completed - Clinical trials for Non Small Cell Lung Cancer

AIMN Multicenter Study: 18 F-FDG PET-CT With or Without Contrast Medium in the Staging and Radiation of Lung Cancer?

Start date: April 14, 2009
Phase:
Study type: Observational

Accurate staging of patients with non-small cell cancer (NSCLC) is of fundamental importance both for the correct choice of treatment plan and for prognosis. Numerous studies have demonstrated the added value of co-registration of functional PET images and anatomical CT images using hybrid PET-CT tomographs and the consequent benefits on the choice of treatment in patients with NSCLC. Currently in most PET centers CT is performed with a "low dose" technique and is used exclusively as a transmissive source for attenuation correction and anatomical localization. The availability of new generation hybrid tomographs allows for "diagnostic" CT examinations (contrast CT) to be performed with a standard dose of radiation and with the use of intravenous and/or oral iodinated contrast medium (contrast medium). Little data is currently available on the added value of a PET-CT scan performed in a single session compared to PET-CT performed independently and, generally, subsequently to CT scan. The objective of the study is to evaluate the ability to correctly define the accuracy in localizing and characterizing lung "lesions" in patients with confirmed NSCLC, in the staging or restaging phase, through the use of: PET-CT "low-dose" and PET contrast CT. The effects of the two procedures on the patient's quality of life and on the costs incurred by the patient and the healthcare service will also be evaluated.

NCT ID: NCT06167941 Completed - Clinical trials for Expression of Integrin a?ß3 in Lung Cancer

Identification of Integrin ab Expression in Lung Cancer Patients

Start date: December 19, 2019
Phase:
Study type: Observational

It has been reported that the expression rates of integrin αvβ3 and integrin αvβ5 in NSCLC are 89% and 100%, respectively. Among RGD (Arg-Gly-Asp) peptides, cRGDyK peptide (cRGD) known as integrin ανβ3 and ανβ5 antagonist has been widely used for targeting various cancers including NSCLC, glioblastoma, and colon carcinoma as well as prostate cancer. In this study, the investigators aim to analysis the expression of integrin ανβ3 in lung cancer patients.